Purple Biotech
PPBT
7 hedge funds and large institutions have $321K invested in Purple Biotech in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
18% less capital invested
Capital invested by funds: $390K → $321K (-$69K)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
+$61.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.64K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
-$21K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$14.6K |
| 3 |
MC
Menta Capital
San Francisco,
California
|
-$7.29K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7.29K |
| 5 |
AG
Advisor Group
Phoenix,
Arizona
|
-$3.64K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MC
1
Menta Capital
San Francisco,
California
| $111K | -$7.29K | -2 | -5% |
|
2
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $86K | – | – | – |
|
|
PVH
3
Psagot Value Holdings
Tel Aviv,
Israel
| $53K | +$61.9K | +17 | New |
|
|
AG
4
Advisor Group
Phoenix,
Arizona
| $27K | -$3.64K | -1 | -10% |
|
|
VKH
5
Virtu KCG Holdings
New York
| $21K | -$14.6K | -4 | -36% |
|
|
6
Citadel Advisors
Miami,
Florida
| $17K | +$3.64K | +1 | +20% |
|
|
7
UBS Group
Zurich,
Switzerland
| $6K | -$7.29K | -2 | -50% |
|
|
ARTA
8
A.R.T. Advisors
New York
| – | -$21K | -5 | Closed |
|
PPBT Hedge Fund Activity: Q2 2017 in Review
7 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q2 2017, worth a combined $321K — down 18% from $390K a quarter earlier.
Fund positioning in PPBT was balanced in Q2 2017: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 4 trimmed.
The largest buyer was Psagot Value Holdings, opening a new position worth an estimated $61.9K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $21K sold.
- 7 institutional investors held Purple Biotech (PPBT) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $321K of Purple Biotech stock for Q2 2017, down 18% quarter-over-quarter.
- 1 fund opened new Purple Biotech positions in Q2 2017 and 1 closed out, a net change of 0 holders.
- The largest Purple Biotech buyer in Q2 2017 was Psagot Value Holdings, an estimated $61.9K added.
- The largest Purple Biotech seller in Q2 2017 was A.R.T. Advisors, an estimated $21K sold.
Based on aggregated 13F filings for Q2 2017.